Using the Past to Inform the Future: Anti-VEGF Therapy as a Road Map to Develop Novel Therapies for Diabetic Retinopathy

Therapies targeting vascular endothelial growth factor (VEGF) are revolutionizing the treatment of diabetic retinopathy (DR) and diabetic macular edema (DME). In August 2012, ranibizumab, a monoclonal antibody fragment targeting VEGF designed for ocular use, became the first and only U.S. Food and D...

Descripción completa

Detalles Bibliográficos
Autores principales: Titchenell, Paul M., Antonetti, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2013
Materias:
Perspectives in Diabetes
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3661651/
https://www.ncbi.nlm.nih.gov/pubmed/23704522
http://dx.doi.org/10.2337/db12-1744

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3661651/
https://www.ncbi.nlm.nih.gov/pubmed/23704522
http://dx.doi.org/10.2337/db12-1744

Ejemplares similares